This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Conventional wet chemistry including the Winkler method for dissolved oxygen, precipitation, filtration for solids, acidification, neutralization, titration etc. Colorimetric methods such as MBAS assay which indicates anionic surfactants in water and on site comparator methods to determine chlorine and chloramines. Nephelometers are used to measure solids concentrations as turbidity. These methods are generally robust and well tried and inexpensive, giving a reasonable degree of accuracy at modest sensitivity. Electro chemistry including pH, conductivity and dissolved oxygen using oxygen electrode. These methods yield accurate and precise results using electronic equipment capable of feeding results directly into a laboratory data management system Spectrophotometry is used particularly for metallic elements in solution producing results with very high sensitivity, but which may require some sample preparation prior to analysis and may also need specialized sampling methods to avoid sample deterioration in transit. Chromatography is used for many organic species which are volatile, or which can yield a characteristic volatile component of after initial chemical processing. Ion chromatography is a sensitive and stable technique that can measure lithium, ammonium NH4 and many other low molecular weight ions using ion exchange technology. Gas chromatography can be used to determine methane, carbon dioxide, cyanide, oxygen, nitrogen and many other volatile components at reasonable sensitivities.
== As food == Partly in consequence of its size, the giant gourami is a significant food fish, and in its native regions it has been harvested as a customary food source. In Southeast Asian cuisine, gourami is highly valued as food due to its thick flesh, texture and flavour. Unlike carp and milkfish, gouramis do not have fine bones within their flesh, which has increased their market value. In Southeast Asian market, gourami is one of the most highly-valued freshwater food fish. Gourami flesh is rich in protein and minerals. It is a popular food fish in Indonesian, Malaysian and Thai cuisines. Gouramis are particularly popular in Sundanese cuisine of Indonesia, where they often being fried as ikan goreng, grilled as ikan bakar or cooked with spice inside a banana leaf wrap as pepes. In some parts of Southeast Asia, they are salted to preserve and prolong shelf life.
=== Screening glucose challenge test === The screening glucose challenge test (sometimes called the O'Sullivan test) is performed between 24 and 28 weeks and can be seen as a simplified version of the oral glucose tolerance test (OGTT). No previous fasting is required for this screening test, in contrast to the OGTT. The O'Sullivan test involves drinking a solution containing 50 grams of glucose and measuring blood levels one hour later. If the cut-off point is set at 140 mg/dL (7.8 mmol/L), 80% of women with GDM will be detected. If this threshold for further testing is lowered to 130 mg/dL, 90% of GDM cases will be detected, but there will also be more women who will be subjected to a consequent OGTT unnecessarily.
Sources: en.wikipedia.org
Notch proteins are a family of type 1 transmembrane proteins that form a core component of the Notch signaling pathway, which is highly conserved in animals. The Notch extracellular domain mediates interactions with DSL family ligands, allowing it to participate in juxtacrine signaling. The Notch intracellular domain acts as a transcriptional activator when in complex with CSL family transcription factors. Members of this type 1 transmembrane protein family share several core structures, including an extracellular domain consisting of multiple epidermal growth factor (EGF)-like repeats and an intracellular domain transcriptional activation domain (TAD). Notch family members operate in a variety of different tissues and play a role in a variety of developmental processes by controlling cell fate decisions. Much of what is known about Notch function comes from studies done in Caenorhabditis elegans (C. elegans) and Drosophila melanogaster. Human homologs have also been identified, but details of Notch function and interactions with its ligands are not well known in this context.
This convinced Macleod to divert the whole laboratory to insulin research and to bring in the biochemist James Collip to help with purifying the extract. The first human clinical trial was unsuccessful. Banting was insufficiently qualified to participate and felt sidelined. By the winter of 1922, he was certain that all Macleod's colleagues were conspiring against him. There was a reported physical altercation between Banting and Collip, as Banting saw Collip's breakthrough on alcohol purification as a threat, while Collip was reluctant to share the details. Collip threatened to leave because of the strained atmosphere but the encouragement of others who saw the potential of their research prevented escalation of the conflict. In January 1922, the team performed the first successful clinical trial, on 13-year-old Leonard Thompson, and it was soon followed by others. Although all the team members were listed as co-authors of their publications, Banting still felt overlooked, because Macleod took over the coordination of clinical trials and the acquisition of larger amounts of extract. Macleod's presentation at a meeting of the Association of American Physicians in Washington, D.C., on 3 May 1922 received a standing ovation, but Banting and Best refused to participate in protest. At that time, demonstrations of the method's efficiency drew huge public interest, because the effect on patients, especially children, who until then were bound to die, seemed almost miraculous. The pharmaceutical company Eli Lilly & Co.
=== Programmed cell death === Dysregulation of apoptosis (programmed cell death) is believed to play a role in the pathogenesis of a variety of autoimmune diseases, though its role in Sjögren's disease is controversial. Both the Fas and Fas ligand proteins are overexpressed in primary Sjögren's patients. Expression of BCL-1, which is known to downregulate apoptosis, was found significantly reduced in acinar and ductal epithelial cells of Sjögren's patients compared to healthy people. In situ studies did not show increased apoptosis among glandular epithelial cells but did show reduced apoptosis among infiltrating mononuclear cells. Reduced apoptosis was also implicated in the accumulation of autoreactive B-cells found in the glands. The relationship between autoantibodies expressed in Sjögren's disease and apoptosis remains an area of active research.
Certain chemicals, including hormones, can influence the composition of the ligaments. An example of this is seen in the menstrual cycle, where hormones are secreted to create changes in the uterine and pelvic floor fascia. The hormones are not site-specific, however, and chemoreceptors in other ligaments of the body can be receptive to them as well. The ligaments of the knee may be one of the areas where this happens, as a significant association between the ovulatory phase of the menstrual cycle and an increased likelihood for an anterior cruciate ligament injury has been demonstrated.
Sources: en.wikipedia.org
=== Mechanisms and therapeutics for neurodevelopmental disorders === Sur’s group has applied this understanding of plasticity to study disorders of brain development. Rett Syndrome is a devastating neurodevelopmental disorder caused by mutations in MECP2, a transcriptional regulator. Sur hypothesized that a core mechanism of Rett Syndrome is the persistence of immature synapses which may be induced to mature. Rett model mice indeed have a deficit in PI3K/Akt/Erk signaling and PSD95 expression, leading to immature excitatory synapses and prolonged visual cortex plasticity that extends into adulthood. Application of IGF1(1-3) peptide, which degrades IGF binding proteins produced by astrocytes and enhances IGF1 availability, and of full-length IGF1, upregulates these signals to restore normal synaptic plasticity and function and improve behavioral phenotypes. Human Rett IPSC-derived neurons show deficits in IGF1 and similar effectiveness of IGF1 in restoring PI3K, AKT and S6 signals. Based on the lab’s work, an IGF1(1-3) mimetic – trofinetide - was employed in clinical trials for Rett Syndrome. In 2023, trofinetide was approved by the FDA as the first treatment for Rett Syndrome. This work has played an important part in raising optimism that even major disorders of brain development may be treated effectively when understood mechanistically.
Anti-U1 RNP antibodies can be detected using blood tests such as enzyme-linked immunosorbent assay (ELISA), immunoblotting, and multiplex immunoassays. These tests are usually performed after a positive antinuclear antibody (ANA) test or when a patient has symptoms of an autoimmune connective tissue disease. The antibodies can also be found in other autoimmune disorders; the results are interpreted together with a patient's symptoms and other findings instead of being used to make a diagnosis.
== Trafficking == The Golden Triangle (Southeast Asia), specifically Shan State, Myanmar, is the world's leading producer of methamphetamine as production has shifted to ya ba and crystalline methamphetamine, including for export to the United States and across East and Southeast Asia and the Pacific. Concerning the accelerating synthetic drug production in the region, the Cantonese Chinese syndicate Sam Gor, also known as The Company, is understood to be the main international crime syndicate responsible for this shift. It is made up of members of five different triads. Sam Gor is primarily involved in drug trafficking, earning at least $8 billion per year. Sam Gor is alleged to control 40% of the Asia-Pacific methamphetamine market, while also trafficking heroin and ketamine. The organization is active in a variety of countries, including Myanmar, Thailand, New Zealand, Australia, Japan, China, and Taiwan. Sam Gor previously produced meth in Southern China and is now believed to manufacture mainly in the Golden Triangle, specifically Shan State, Myanmar, responsible for much of the massive surge of crystal meth in circa 2019. The group is understood to be headed by Tse Chi Lop, a gangster born in Guangzhou, China who also holds a Canadian passport. Liu Zhaohua was another individual involved in the production and trafficking of methamphetamine until his arrest in 2005. It was estimated over 18 tonnes of methamphetamine were produced under his watch.
Sculptra is a proprietary formulation of poly-L-lactic acid (PLLA) that is an FDA-approved dermal filler manufactured by Dermik Laboratories, which conducts the American business of Aventis Dermatology, the global dermatology unit of Aventis (of Sanofi-Aventis). PLLA was approved by the FDA on August 3, 2004, for the treatment of facial fat loss (also called facial lipoatrophy). According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically "for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV). Facial lipoatrophy is a condition in which people lose fat in their faces, especially in their cheeks and around their eyes and temples. People with HIV who take anti-HIV drugs may develop HIV-associated lipodystrophy. Sculptra was subsequently approved by the FDA for use with non-HIV patients with wrinkles, despite substantial complications reported to the FDA. After the injection, it will take around 1 to 1.5 months to grow natural collagen. Bruising and swelling may occur post injection, which will go down within a week. After the injection, patients are directed to massage the treatment area in order to maintain smooth, level and evenly distributed results and prevent granuloma formation.
Biko opposed any collaboration with the apartheid government, such as the agreements that the Coloured and Indian communities made with the regime. In his view, the Bantustan system was "the greatest single fraud ever invented by white politicians", stating that it was designed to divide the Bantu-speaking African population along tribal lines. He openly criticised the Zulu leader Mangosuthu Buthelezi, stating that the latter's co-operation with the South African government "[diluted] the cause" of black liberation. He believed that those fighting apartheid in South Africa should link with anti-colonial struggles elsewhere in the world and with activists in the global African diaspora combating racial prejudice and discrimination. He also hoped that foreign countries would boycott South Africa's economy. Biko believed that while apartheid and white-minority rule continued, "sporadic outbursts" of violence against the white minority were inevitable. He wanted to avoid violence, stating that "if at all possible, we want the revolution to be peaceful and reconciliatory". He noted that views on violence differed widely within the BCM – which contained both pacifists and believers in violent revolution – although the group had agreed to operate peacefully, and unlike the PAC and ANC, had no armed wing. A staunch anti-imperialist, Biko saw the South African situation as a "microcosm" of the broader "black–white power struggle" which manifests as "the global confrontation between the Third World and the rich white nations of the world".
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.